Rhythm Pharmaceuticals, Inc.

RYTM

US76243J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 05/07/2024 BST			5-day change	1st Jan Change
42.28 ^USD	+3.60%		+2.97%	-8.03%

07-01	Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index	CI
07-01	Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell Microcap Index	CI

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index

July 30, 2024

Latest news about Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Growth Index	06-30	CI
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell Microcap Index	06-30	CI
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell Microcap Growth Index	06-30	CI
Rhythm Pharmaceuticals, Inc.(NasdaqGM:RYTM) dropped from Russell 3000E Index	06-30	CI
Rhythm Pharmaceuticals Says EMA Committee Backs Expanded Authorization for Obesity Drug	06-28	MT
Rhythm Pharmaceuticals, Inc. Receives Positive CHMP Opinion for IMCIVREE (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients Between 2 and 6 Years Old with Bardet Biedl Syndrome	06-28	CI
Transcript : Rhythm Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	06-10
Rhythm Pharmaceuticals' Imcivree Gains UK Recommendation for Treating Bardet-Biedl Syndrome	05-22	MT
Transcript : Rhythm Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 02:20 PM	05-14
BofA Downgrades Rhythm Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $42 From $49	05-08	MT
Rhythm Pharmaceuticals' Q1 Net Loss Widens as Revenue Increases; Shares Fall Pre-Bell	05-07	MT
Transcript : Rhythm Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 07, 2024	05-07
Earnings Flash (RYTM) RHYTHM PHARMACEUTICALS Reports Q1 Revenue $26M, vs. Street Est of $26.9M	05-07	MT
Rhythm Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
Rhythm Pharmaceuticals, Inc. Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting	05-06	CI
Rhythm Pharmaceuticals, Inc. Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in the Lancet Diabetes & Endocrinology	04-29	CI
Wells Fargo Trims Price Target on Rhythm Pharmaceuticals to $52 From $53, Maintains Overweight Rating	04-18	MT
Rhythm Pharmaceuticals to Sell $150 Million in Series A Convertible Preferred Stock	04-01	MT
Rhythm Pharmaceuticals, Inc. announced that it expects to receive $150 million in funding from Perceptive Advisors LLC, C2 Life Sciences, Llc, Perceptive Discovery ID LP	03-31	CI
Rhythm Pharmaceuticals Doses First Patients in Phase 1 Trial of Potential Obesity Therapy	03-25	MT
Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist	03-25	CI
Rhythm Pharmaceuticals Insider Sold Shares Worth $735,600, According to a Recent SEC Filing	03-22	MT
Rhythm Pharmaceuticals Insider Sold Shares Worth $707,005, According to a Recent SEC Filing	03-22	MT
Perceptive Advisors Engages in Discussion with Rhythm Pharmaceuticals	03-20	CI
Rhythm Pharmaceuticals Insider Sold Shares Worth $608,498, According to a Recent SEC Filing	03-20	MT

Chart Rhythm Pharmaceuticals, Inc.

Duration

Period

More charts

Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS); or Bardet-Biedl syndrome (BBS). It is evaluating setmelanotide in Phase II and III trials for the treatment of obesity due to variants in one of numerous genes associated with the MC4R pathway.

Sector

Biotechnology & Medical Research

Calendar

29/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Rhythm Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

42.28 USD

Average target price

57.22 USD

Spread / Average Target

+35.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
RHYTHM PHARMACEUTICALS, INC.	-8.03%	2.58B
VERTEX PHARMACEUTICALS INCORPORATED	+16.61%	122B
REGENERON PHARMACEUTICALS, INC.	+17.75%	112B
ARGENX SE	+17.23%	25.91B
BIONTECH SE	-24.11%	19.33B
GENMAB A/S	-18.56%	16.17B
BEIGENE, LTD.	-18.47%	15.6B
WUXI APPTEC CO., LTD.	-47.75%	14.65B
SAREPTA THERAPEUTICS, INC.	+57.35%	14.34B
NEUROCRINE BIOSCIENCES, INC.	+5.62%	14B

Bio Therapeutic Drugs